A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00309725|
Recruitment Status : Completed
First Posted : April 3, 2006
Last Update Posted : May 18, 2011
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: galantamine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||139 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study.|
|Actual Study Completion Date :||October 1999|
U.S. FDA Resources
- Hourly mean heart rates and PR intervals during each of the 24-hour Holter monitoring periods; Twenty-four hour mean, minimum and maximum heart rates and PR intervals during each of the 24-hour Holter monitoring periods
- Pharmacokinetics and other safety parameters including ECG parameters were other parameters of interest.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00309725
|Study Director:||Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|